Outset Medical (NASDAQ: OM), a medical technology company, reported second-quarter earnings for 2024 that missed market expectations, primarily due to a slower ramp-up of its TabloCart product and an extended sales cycle.
Despite these challenges, the company highlighted several positive aspects of its performance, such as strong treatment sales and the growth of its installed base for the Tablo console. The earnings call detailed the company’s strategy to overcome current hurdles and its focus on long-term growth.
Key Takeaways
- Outset Medical’s Q2 earnings were below expectations, impacted by a slower TabloCart ramp-up and a lengthier sales cycle.
- Non-GAAP gross margin exceeded forecasts at 37.3%, with product margin at 44.8%.
- The company is retooling its commercial team and introducing new sales processes to improve enterprise opportunities.
- Recurring revenue increased by 24% in Q2 2024 compared to Q2 2023.
- Outset Medical reduced annualized spending by about $17 million and expects OpEx for 2024 to be around $120 million.
- The company ended Q2 with $198.2 million in cash and anticipates an inventory increase in the second half of the year before a decrease.
- Every console sold is expected to generate $15,000 to $20,000 in annual recurring revenues.
- The company remains focused on returning to sustainable top-line growth and is confident in its long-term revenue prospects.
Company Outlook
- Revenue for the second half of 2024 is projected to mirror the first half, with an estimate of around $110 million.
- Non-GAAP gross margin is expected to remain in the low to mid-30% range.
- The company anticipates non-GAAP operating expenses for 2024 to be approximately $120 million.
Bearish Highlights
- Outset Medical faced a sales slowdown and lower revenue in Q2 2024.
- A cyber attack disrupted operations, contributing to the challenges.
- The company has lowered its guidance for the year due to sales force and process restructuring.
Bullish Highlights
- The company has a strong foundation in recurring revenue and has improved its gross margin by more than 70 percentage points since Q3 2020.
- Outset Medical is adjusting its sales team and processes to tap into high customer demand and commitment.
- Approximately 60% of deals in the pipeline are valued at $1 million or more, indicating potential for large enterprise deals.
Misses
- The company did not meet revenue expectations for Q2 2024.
- The introduction of TabloCart and other factors elongated the sales cycle, impacting earnings.
- Guidance for the year was adjusted downward due to restructuring disruptions.
Q&A Highlights
- Executives stated that they can achieve a cash flow breakeven at a lower revenue run rate than previously guided.
- They expect the execution transformation to take several quarters to fully implement.
- No specific guidance for 2025 was provided, but the company is optimistic about closing deals in the pipeline.
Outset Medical’s earnings call provided investors with a comprehensive view of the company’s current challenges and its strategies for future growth. While the second quarter of 2024 did not meet expectations, the company’s strong recurring revenue stream and adjustments to its commercial execution strategy offer a positive outlook for the long term. With a focus on large enterprise deals and a robust pipeline, Outset Medical remains confident in its ability to achieve profitability and sustainable top-line growth.
InvestingPro Insights
Outset Medical’s recent earnings report has brought to light several critical factors that investors should consider. According to InvestingPro data, Outset Medical has a market capitalization of $72.93 million, reflecting the company’s size in the competitive medical technology sector. Despite a challenging quarter, Outset Medical’s revenue over the last twelve months as of Q1 2024 stands at $125.08 million, with a growth of 5.74%. This indicates a steady increase in revenue, aligning with the company’s focus on long-term growth.
InvestingPro Tips reveal that analysts have recently revised their earnings upwards for the upcoming period, suggesting optimism about Outset Medical’s future performance despite current headwinds. However, it’s important to note that the company’s stock price movements have been quite volatile, which could be a point of concern for risk-averse investors. Additionally, analysts do not anticipate the company will be profitable this year, which is consistent with the company’s own admissions during the recent earnings call.
A closer look at the company’s financial health shows that while Outset Medical is quickly burning through cash, their liquid assets exceed short-term obligations, providing some financial stability in the near term. The company operates with a moderate level of debt, which is a positive sign for stakeholders considering the company’s investment in growth and transformation strategies.
For those interested in deeper analysis and more InvestingPro Tips, there are additional insights available on the InvestingPro platform, which currently lists several more tips for Outset Medical at https://www.investing.com/pro/OM.
The company’s price at the previous close was $3.4, and while the price has fallen significantly over the last year, the fair value assessed by analysts stands at $6, with InvestingPro’s fair value estimation slightly lower at $4.51. This disparity suggests that there may be an opportunity for value investors, assuming the company can turn its strategy into tangible results.
Investors should keep an eye on Outset Medical’s next earnings date on November 5, 2024, to assess the company’s progress on its commercial execution strategy and its impact on financial performance.
Full transcript – Outset Medical Inc (OM) Q2 2024:
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Outset Medical Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. (Operator Instructions) Please be advised that today’s conference is being recorded. I would like now to turn the conference over to Jim Mazzola, Head of Investor Relations. Please go ahead.
Jim Mazzola: Okay. Thank you very much. Good afternoon, everyone, and sorry for starting a few minutes late here. Welcome to our second quarter 2024 earnings call. Here with me, as always, are Leslie Trigg, Chair and Chief Executive Officer; and Nabeel Ahmed, Chief Financial Officer. We issued a news release after the close of market today, which can be found on the Investor page of outsetmedical.com. This call is being recorded and will be archived on the Investors section of our website. It’s our intent that all forward-looking statements made during today’s call will be protected under the Private Securities Litigation Reform Act of 1995. These statements relate to expectations or predictions of future events are based on our current estimates and various assumptions and involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied. Outset assumes no obligation to update these statements. And for a list — and description of risks and uncertainties associated with our business, please refer to the Risk Factors section of Outset’s public filings with the SEC, including our latest annual and quarterly reports. Leslie?
Leslie Trigg: Thanks, Jim. Good afternoon, everyone, and thank you for joining us. I’ll begin with our results in the second quarter, which on the top line, we’re below our expectations as we work through the re-ramp of TabloCart and saw new evidence of our sales cycle elongating. Areas of strength in the quarter included treatment sales, which grew 25% year-over-year; console ASP, which increased more than 8% year-over-year; the console installed base, which grew 18% year-over-year; and the number of acute facilities using Tablo, which grew 16% year-over-year. Non-GAAP gross margin came in substantially above our expectations at 37.3% for the quarter with product margin coming in at 44.8%. Despite the progress, second quarter revenue of $27.4 million was lighter than expected and driven entirely by console sales below our forecast. While the return of TabloCart was helpful in advancing some of the acute deals in our pipeline, the ship hold masks what we now recognize, which is the need for commercial execution changes to better position ourselves to capitalize on enterprise opportunities that typically come with a longer sales cycle. Before I get to those changes, I think it may be helpful to reflect on the growth we’ve experienced since our launch in 2019, which was driven by early market adopters. These innovators and visionaries largely in the acute setting where we have scale and now low double-digit market share. We’re the first to leave their long-standing outsourced relationships motivated by gaining control over their financial, operational and clinical destiny. The support from early adopters of Tablo and the in-sourcing model has been essential to demonstrating the benefits Tablo provides that will fuel our next stage of growth. This next stage of growth comes as we extend past the early enterprise adopters and use our foothold to expand into the mainstream enterprise adopters. These customers are deliberate, consensus-driven and process-oriented. Purchase decisions are contemplated with enterprise conversion in mind. And accordingly, the sales cycle often takes longer as it requires a larger group of stakeholders buying in. We’ve learned that success with mainstream enterprise adopters require a change in how we sell, who we sell and the process we use to get there. For example, we’ve identified the need to sell more broadly within the C-suite and established commitment across a larger base of stakeholders deeper within the system to gain buy-in. We’ve also recognized that our team needs to demonstrate exceptional consultative and change management skills as they work with large health systems on potential enterprise conversions. As we advance the insourcing movement from the early enterprise adopters into mainstream enterprise adoption, it requires changes in how we go to market, which involves three big shifts in our commercial approach. First, retooling our commercial team by infusing our capital sales team with individuals who have a different profile and skill set and ensuring we have the right talent in each role. Second, introducing a new capital sales process with greater specificity, accountability and discipline. And third, injecting rigorous sales management inspection at every step along the way to improve capital sales forecasting and the timing of close. This work is already underway. For example, we now have in place a sales leadership team with deep capital equipment experience centered around enterprise selling. We have also restructured our sales organization and trained them on our new enterprise sales approach. As we effectuate these changes, the result will be a resized and more nimble sales team and a methodical enterprise sales process commensurate with our expected future growth trajectory. Given the depth and breadth of the sales team and process restructuring, we expect it to take several quarters to fully implement and realize the many benefits that will come from it. As we look ahead to the second half of the year, we now know it will not be possible to execute this transformation given the expected accompanying disruption while simultaneously delivering on the ramp we previously forecasted. As a result, we expect the second half of 2024 will look similar to the first half with expected revenue for the year of approximately $110 million. We will continue to ensure spending is aligned to this new revenue outlook as we drive toward profitability. We expect this restructuring and optimization to deliver additional annualized savings into 2025. While the transition to enterprise sales is challenging for any company, we believe the benefits are substantial in terms of deal size and revenue growth. While this transition is having a near-term negative impact on our business, we have strong conviction that it’s the right thing for our business over the long term. What we’re observing is not a lack of demand or losing opportunities to a competitor. Tablo remains highly differentiated in delivering the clinical, financial, and operational improvements healthcare providers need in both the acute and home settings. The quality and depth of demand in our pipeline is stronger than we have ever seen to date with a high percentage of large deal sizes over $1 million each. What we’re experiencing is a temporary dislocation of converting the pipeline to revenue on our timeline due to the changes in customer profile and process and the improvements needed in our own sales execution. With our installed base now at roughly 5,700 consoles, the number of treatments performed each month on Tablo continues at record levels. Treatment orders remain strong and our recurring revenue business model continues to distinguish itself. During the second quarter, recurring revenue grew 24% from the second quarter of 2023 with gross margin materially expanding as it has each quarter for more than three years. Non-GAAP gross margin in the second quarter reached a record 37.3% with product margin at 44.8% and service and other margin at 19.8%. Before turning the call over to Nabeel, I’d like to add a few highlights from our end market. For example, in the acute and subacute settings, we added nearly 30 new accounts during the quarter and continued strategic insourcing rollout at two of the largest health systems in the country. Data from one of our ICU customers was also published in a medical journal and showed a 40% reduction in mean length of stay, which resulted in savings during the measurement period of more than $1 million. In the home, we continue to see industry leading retention rates and look forward to publishing more data from our home registry later this year. At the end of the second quarter, our 90-day retention rate remained at 90% versus the 55% average reported with the incumbent home hemodialysis device. And our cumulative rate remains at just approximately 10%. Our home centers continue to grow with multiple mid-sized dialysis organizations and skilled nursing facilities expanding with Tablo. With that, I’ll now turn it over to Nabeel.
Nabeel Ahmed: Thanks, Leslie. Hello, everyone. Revenue for the second quarter was $27.4 million, a 3% decline from the first quarter, and driven solely by softness in console revenue for the reasons Leslie described. Product revenue of $19.2 million included console revenue of $7.2 million, which declined 22% from the first quarter. The other component of product revenue is consumable sales, which performed very well as utilization continued to be strong. Consumable revenue rose nearly 8% sequentially and more than 25% from the second quarter of last year to nearly $12.1 million. Service and other revenue also performed well, increasing to $8.2 million, up 5% sequentially and 22% year-over-year. We were encouraged to see that console ASP remained strong across all end markets as a result of our disciplined pricing and strong uptake of our Tablo PRO+ offering with acute customers. Now moving to our second quarter gross margin and operating expenses, which as a reminder, reflects our non-GAAP results. Please refer to the reconciliation of GAAP to non-GAAP measures found in today’s earnings release. Gross margin of 37.3% increased more than six percentage points from the first quarter and more than 14 percentage points from the second quarter of last year. As Leslie mentioned, we saw strong underlying dynamics within both product gross margin, which was a record 44.8% and service and other gross margin at 19.8%. Expanding gross margin remains a hallmark of our story and continues to be driven by our product mix, console cost-down programs, strong utilization and service renewals. BK’s (ph) gross margin is sensitive to mix, it may fluctuate a bit on a quarter-to-quarter basis, but we remain confident in our ability to reach our next milestone at 50%. Operating expenses of $31.2 million declined 11% as compared to the first quarter and 25% from the prior year period, driven by our ongoing focus on expense management and the restructuring actions we’ve taken since the fourth quarter of 2023. Non-GAAP net loss was $24.7 million or $0.47 per share, materially lower on a sequential and year-over-year basis. Net loss for the second quarter was 16% lower than the first quarter and 27% lower than the second quarter of 2023, reflecting the positive results of our drive to profitability. These results also reflect our ongoing focus on gross margin expansion, which we’ve achieved consistently for three years now and on our commitment to aligning OpEx with our level of revenue growth. I want to step back for a moment here and focus on our ongoing commitment towards reaching profitability. We have, in previous quarters, underscored our alignment with shareholders on this goal, and I wanted to update you on our related actions. First, from a revenue perspective, our business is structurally designed for both revenue growth over the long term and for gross margin expansion. Every console we sell today is expected to generate between $15,000 to $20,000 of annual recurring revenues. These revenues have historically proven to be very predictable and come at high gross margins with high marginal operating leverage. Indeed, our recurring revenues grew by 24% in Q2 2024 compared to Q2 of 2023 and by 27% if you compare the first half of 2024 to the first half of 2023. Once we get our console placement engine ramps, we should expect that these recurring revenues will continue their contribution to growth and gross margin expansion. We believe that recurring revenues on an annual basis should continue to be over half of our total revenues as we move forward. Second, we continue to deliver on our gross margin expansion initiatives and have improved gross margin by more than 70 percentage points since Q3 of 2020, our first publicly reported quarter. In addition to the gross margin expansion that is structurally driven by our business, we expect to continue our work to improve gross margin over time as we continue our cost-reduction initiatives across product and service. Third, we are focused on ensuring that our OpEx scales at a rate that is aligned with our expected rate of revenue growth and with an eye to its profitability. Since the fourth quarter of 2023 and inclusive of the actions we discussed today, we have reduced our annualized spending by roughly $17 million, putting our run rate non-GAAP operating expenses at just over $100 million. Our non-GAAP operating loss for the second quarter was $21 million, the lowest quarterly level its been at since we achieved commercial scale in 2021, reflecting the work we’ve done around driving recurring revenue growth, expanding gross margin and managing OpEx. And finally, moving to our balance sheet. We are focused on additional opportunities to reduce the working capital impacts on cash through supply chain and manufacturing strategies to optimize inventory levels. We expect that inventory will step up over the second half of this year before burning down beyond that period. We remain well financed, ending the second quarter with $198.2 million in cash, cash equivalents, short-term investments and restricted cash. Turning to our outlook for full year 2024. We now expect revenue of approximately $110 million. Our base assumption is that console revenue in the second half is similar to what we reported for the first half. With strong utilization, we would expect recurring revenue to continue to perform well as it has consistently done. Turning to gross margin. With our continued outperformance, we have increased conviction in our guidance for 2024 non-GAAP gross margin. For the full year, we are updating this guidance to now be in the low to mid-30% range. Again, gross margin expansion is driven by recurring revenues from a larger installed base, service leverage and console cost-down programs. Turning now to OpEx for 2024. We expect to realize additional benefit from — we expect to realize additional benefit this year from the work we have done. We now anticipate that OpEx for 2024 will be roughly $120 million, down from our prior guidance of $125 million to $130 million. As I said earlier, since the fourth quarter of 2023, we have reduced our annualized spending by roughly $70 million, putting our run rate non-GAAP operating expenses at just over $100 million. And finally, with our strong value proposition across two large end markets, wide competitive moat and broad integrated offering of products and service, we remain bullish on the long-term revenue growth profile. We will revisit our long-term outlook once the enterprise sales transition is complete and believe that following this transition, we will return to a strong, consistent top line growth. With that, I’ll turn the call back over to Leslie.
Leslie Trigg: Thanks, Nabeel. We are clearly dissatisfied with our performance and we are making significant and difficult changes in our people, our processes and our commercial approach as a result. While it has caused disruption and it will continue to disrupt our near-term comp growth trajectory, we are firmly convinced that these are the right steps to return the company to meaningful, sustainable top line growth. Further, the fundamentals of this market, the business model and our products remain firmly intact. We are penetrating one of the largest healthcare markets in the world with over 85 million dialysis treatments performed each year in the United States alone. We have a proven business model. During just the past three years, we have increased recurring revenue from about 30% to well above 50% of total revenue. When Tablo consoles are sold and installed their use. And we have executed very well to expand gross margin consistently since our IPO, again, demonstrating the strength of this business model over time. We remain as committed as ever to reaching profitability. This is a business that can be profitable and we believe will be profitable due to a proven foundation of predictable recurring revenue, our gross margin profile and inherent operating leverage. What we do well goes far beyond the technology. Our product is not just a device that change management and customer success expertise that is proprietary and very hard to replicate. We now have data from hundreds of customers that support the business case and the value proposition of in-sourcing with Tablo. We help save healthcare providers money, simplify their operations and improve the quality of living for their patients. These fundamental benefits are more important than ever, and Tablo brings a highly differentiated, difficult-to-copy product market fit to them. With that, I think we are ready for Q&A. Operator, please open the lines.
Operator: (Operator Instructions) And our first question will come from Marie Thibault with BTIG. Your line is open.
Marie Thibault: Hi, good evening. Thanks for taking the question. I want to start here with just trying to understand a little bit more of the challenges you’re facing. I hate to be dense here, but enterprise sales, on the little juggernaut to me, I want to understand who the enterprise customers are, how different that is from the MDOs that you had been targeting. And then are there structural challenges to the market? Is it competition? What else is making it hard for Tablo to compete for console sales here?
Leslie Trigg: Yes. Thanks, Marie, for the questions. Yes, a couple of things. So first of all, maybe I’ll work backwards here. Short answer, no. No structural changes or challenges that we’re facing here. In a good way, in a bad way, we own this. The changes we need to make are entirely in our control and require shifts and adjustments in our sales team, in our sales processes, in our pipeline management and our deal control. We do know how to do this. We have successfully closed large enterprise-level deals before. We now need to do so more consistently across the country. So that’s maybe point one. In terms of the first part of your question, what are the real differences between the customer segment? I think what we’ve recognized in hindsight is that the first phase of our growth was fueled by early adopters. And those decision-making processes are different. Early adopters tend to move more quickly, tend to move with less consensus, fewer steps in the process and are really willing to kind of move quickly and sometimes without all the evidence in hand. We have moved through that segment. We’re now in the low double-digit market penetration zone, which kind of aligns actually to that plastic adoption curve and the early adopters, the visionaries and innovators that tend to go first within it. Now we have earned the right to penetrate into mainstream enterprise adopters and their decision-making processes are different. It is more consensus driven. There are more stakeholders both vertically up and down within these health systems and across from finance to operations to clinical influencers, and we need to do a better job of building that support top to bottom left to right. So those are some of the differences in the types of deals and the stage that we’re seeing shifting from, again, early adopters of in smaller deals to now a pipeline that has evolved as we see it, to a larger percentage of significant deals. These are deals that are 50-plus consoles, 100-plus consoles. These are customers that are considering enterprise-wide conversions and while that’s actually good news in the sense that the commitment levels and the interest levels are higher and much cheaper. The flip side of that is that it does involve a longer sales cycle, and we need to make the adjustments in our team and our processes to better prosecute that.
Marie Thibault: Understood. That’s very helpful, Leslie. I guess my follow-up here would have to do with the workforce changes you’ve been making. On the last call, you discussed reductions in headcount and a commitment to not impact commercial efforts. Now there’s a discussion of finding the right people for the seat and sort of resizing the team. Is it a smaller sales force that you’re looking at? It does sound like a very different type of person that you’re targeting. Is that targeting done? Is the hiring done and are the right people in place and now we’re selling? Or is there still more evolution to come on the workforce? Thanks for taking the question.
Leslie Trigg: Yes, sure. Of course. Understood. Again, I’ll start with — probably with the last part of your question. So, yes, these individuals, and I’ll start at the leadership level that have a very different profile and more importantly, a track record of kind of being in the end zone and shepherding multimillion dollar deals all the way to the end zone successfully. They are already inside of our organization, not only at the leadership level, but also within our capital sales team. We’ve seen them demonstrate success here already at outset. Now we need to see it happening more broadly and more consistently across the rest of the organization. In terms of the size of the sales force, I would think about it as probably more kind of spans and layers, getting closer to the customer. By and large, the size of the team focused on selling capital is the same. Again, just a very different talent background, level profile and skill sets. The other key — key areas of the commercial team that’s probably underappreciated, and I really want to underscore is our field service and support team. The size of that team isn’t changing at all. The composition isn’t changing. They really are the face of health that they inform the user experience more than probably anybody else on our team and they’re vital to this growth that we continue to see in the recurring revenue base and that part of our organization isn’t changing.
Marie Thibault: Thank you.
Operator: And the next question comes from Rick Wise with Stifel. Your line is now open.
Rick Wise: Good afternoon, Leslie. Like Marie, I’d like to make sure I’m understanding how this all in all makes total sense that bigger contracts, bigger orders, enterprise-wide selling and execution maybe requires evolution. But I guess a two-part question related to that. Looking back at your comments last quarter, it felt like with Tableau cart in hand orders that had been delayed could now be sold. And the — there was a cyber attack that disrupted things, and we would see an acceleration. Help us transition from what you were thinking and understanding about where you were in early mid-May, and where we are now sort of like what happened — what didn’t materialize that you thought was materializing? Is it that you were counting on multiple large orders that didn’t happen? Just trying to understand how we got here. I understand what you’re saying about where you need to go as an organization next…
Nabeel Ahmed: Yeah. Very, very fair set of questions there. Well, first and foremost, I think certainly, in hindsight, with the benefit of hindsight, I think Tableau Cart masked some additional factors that we’re also helping to elongate our sales cycle. We — I think we were pretty clearly slow to recognize it as we focused principally on getting Tableau card back on track and back on market. I think the first thing that we missed, which is now very discernible as we sit here today, is this shift in the composition of our pipeline and in our customer base, again, away from the earlier adopters and toward a very large percentage of deals that are enterprise level with mainstream adopters. Now what that requires is to convert is a much different sales process and sales team than we’ve had in the past. As I’ve mentioned, the process with these customers is more consensus-driven with more stakeholders and more deliberation, which is quite understandable given the level of commitment that they’re contemplating and more steps. I think good news, this shift reflects high demand and a high level of commitment. Again, on the flip side, we need to change, and we need to make adjustments in our commercial execution just to be able to capitalize on that. What — I think what most surface is for us, Rick, thinking back to the second quarter, is while Tableau Curt itself certainly did elongate some of these larger deals, it didn’t alone elongate all of them. And yes, we did expect more of the sort of the Tableau cart occluded deals for lack of better term to advance and to close in the second quarter. And when they didn’t, it really became pretty apparent that there probably was something more going on here, something that we needed to examine on a much deeper level, which really led to our realization that, hey, we’re past the early adopters. We’ve earned the right with our results, with our footprint, with our experience to go after these larger enterprise deals with mainstream customers and go after enterprise-wide conversion, but we’re going to need to change in order to take full advantage of it. I hope that helps.
Rick Wise: Yes. Thank you. And a couple of other questions about as we go through this transition, as you go through this transition, I guess, there’s so many questions here. How does the lower-than-anticipated revenue impact cash flow breakeven, timing, the 50% gross margins? I mean, you reiterated all these things basically. But does the timing change? And well, I’ll stop there. Go ahead. Thank you.
Nabeel Ahmed: Hey Rick, it’s Nabeel. So with respect to cash flow breakeven timing, our run rate OpEx for 2025 and after the actions we’ve taken is now about $100 million. And so that means that at a 50% gross margin, which we continue to have conviction in getting to, we can now get there at a revenue run rate of $200 million, which is actually lower than our previous guidance when it came to breaking even. And then, Rick, as we move a little bit above 50% gross margin, that revenue run rate is below $200 million. Now talking about the gross margin for a minute here, our growth is really underpinned by the recurring revenues that Leslie and I talked about. And these recurring revenues, particularly consumables, come with higher gross margins than consoles. That’s been the case and will continue to be the case. And so the mix shift associated with more recurring revenues actually conceivably accelerates our path to 50%, all else being equal. And so hopefully, that gives you a sense of how we actually break even at a lower run rate and continue to have conviction in that 50% gross margin milestone. Let me pause to see if I answered your question.
Rick Wise: Yeah. That’s very helpful, Nabeel. And I guess last for me for the moment. You’ve guided us to a second half, as you’ve said very clearly, roughly equal to the first half as you go through this sales or execution transition. And again, impossible to answer, I’m sure. But how do we — we have to plug something into our models for 2025 and beyond. Do we — should we imagine — Leslie, do you imagine — do you hope that this is a six-month transition process? I mean, what are you hoping and planning at this point? And that starting from the get-go in 2025, we should — you hope that we’ll be able to see the demand translate into better execution and some of these million-dollar contracts translate into better sales. How do we think about 2025 and beyond, frankly?
Nabeel Ahmed: Sure. Yeah. I have to comment on that and Nabeel jump in at any time. Suffice it to say, in the very immediate short term here, we’re obviously focused on executing this transformation. And I do expect it to take several quarters to fully implement. Again, it’s underway. It’s taking root, but that never happens overnight. And along the way, we’ll get better and better visibility about the timing, the effects, the results, which obviously will put us in a good position to provide guidance for 2025 as we get closer to the turn of the year. Over the longer term, 2025 and beyond, I think about it in a couple of ways. First and foremost, nothing about the fundamentals. The structure of this opportunity has changed. As I said, we own this. We have demonstrated the ability to close large enterprise deals in the past. We just need to do it more consistently across the country in a more standardized fashion. And all the steps needed to get there are in-flight. The strength of our recurring revenue foundation really is a powerful growth engine. We’ve seen that time and again. And in fact, actually, interestingly, our cohort analysis shows that console utilization in the acute and subacute space actually goes up over time as new accounts become more mature accounts. So, that’s obviously very encouraging to see. Second, the growth in our pipeline that I alluded to earlier, it indicates very strong forward demand. The overall pipeline actually has never been larger than it is today and the number of deals with 50 consoles, 100 consoles, several hundred consoles has never been higher. So, this is not a demand problem, where we need to get stronger is converting the pipeline. The changes we need to make in order to do that pertain to sales execution, they are in our control, and we do know how to do this. We just need to do it consistently. My final remark with regard to longer term growth is — it’s kind of a double-edged sword actually, with the deals in our pipeline getting larger, it actually doesn’t take that many deals to close incrementally to drive growth. Now, obviously, near-term here, we’ve seen that work the other way. It’s several deals that are, call it, 50-plus consoles don’t close on the timeline that you expect them to, it has a sizable impact on revenue, which is what we’ve seen happening in Q1 and Q2 and what informed our guidance for the back half of the year. But looking forward, getting back to growth can be achieved with better, more predictable execution on — actually on a relatively small number of larger deals.
Nabeel Ahmed: Rick, if I may, I’d just love to help provide sort of how we think about our model. We’re not providing any guidance for any period beyond 2024 right now, but hopefully, this will give you kind of the color as you think about your models. So, first of all, we always start with the recurring revenues. Implied in our guidance is that recurring revenues will be roughly $80 million or a little bit more for 2024. That’s going to grow in 2025 as the installed base grows and matures as it sort of always has done. Now, as we previously shared, this recurring revenue growth means that we can grow total revenue even if console placements or console revenues remained flat. And then, Rick, any console growth year-on-year easily gets you into the low double-digit growth range for total revenue or beyond. So, again, we’re not giving guidance, but hopefully, that helps you sort of with how we think about the model.
Jim Mazzola: Okay. Thanks, Rick. Next question operator.
Operator: Yes. Our next question comes from Shagun Sing with RBC Capital Markets. Your line is open.
Shagun Sing: Great. Thank you so much. Yes, Leslie, it does seem like there’s an execution issue at outside on multiple fronts. And I’m just wondering, you’re calling out commercial, but is it commercial? Is it strategy? Is it something broader than that? I’m sure you guys have looked into it in more detail. So, can you share what your findings are? And then I’m just curious, how do you know that this is a sales elongation issue? Because to Rick’s question, earlier, we were thinking it’s a Tableau card issue and it’s not being in the market. And perhaps like you can give us some look into the pipeline, where does it stand versus last year? Have you thought of any metrics you’re going to share with us going forward that gives us confidence that you have visibility into this? I know there are a lot of questions, but just how can you make us more comfortable with the story that’s here going forward? Thank you.
Leslie Trigg: Sure. Yes, I’m happy to address those questions. On the pipeline front, compared to last year, the pipeline in totality is significantly larger across the board. And that’s actually across all of our end markets, acute, subacute and home than it was a year ago today, but kind of point one. Another way that we look at our pipeline is by stage, stage of this new sales process that we have introduced and trained everybody too. We have a greater percentage of deals in the late stages of the sales process than we ever have before. So i.e., greater progress through the sales process compared to a year ago this time. And the third thing we look at is deal size. We have a large percentage, approximately 60% a bit above of deals that equate to roughly $1 million or substantially more in deal size sitting in the pipeline. So those are the ways that we look at the pipeline. All of those trend lines are up as you compare them to last year. Regarding your question about, hey, is it execution or is it strategy or other. We feel strongly that it is execution, and I’ll tell you the reasons for that. First and foremost, we now have the largest evidence base we’ve ever had around the financial cost savings that Tablo has driven for customers, the clinical outcomes that it has provided and the operational efficiencies. We have 75 abstracts and 15 papers and innumerable case studies and white papers that all show tangibly the benefits of in-sourcing with Tablo. I have spent a lot of time in the field. I’ll add qualitatively and with our sales team really pressing on, hey, is there something that’s changed in the value proposition or the implementation. And the answer to that has been resoundingly no. The feedback that we continue to get from current customers and prospective customers is their interest level has never been higher around improving their own margins and producing tangible day 1, $1 expense reduction by in-sourcing with Tablo. So I think our strategy is on point with acute, subacute has been one of the fastest-growing market segments for us for the last year or two here with rehab, LTAC and skilled nursing facilities when we look at our expansion with the number of customers and the number of sites using Tablo in the subacute segment, that also is all up and to the right. We talked about 16% growth year-over-year in facility expansion and an 18% growth year-over-year in the installed base, which are data points that do point to a customer validation in the model and in the technology. We have more demand than I ever could have hope for a couple of years ago. What we now need to do is evolve and transition the way we get after it. I would say that, again, our sales team, our sales processes were really oriented around the first part of the market, which for any medical device company are those early adopters. It’s time for us to evolve that so we can reach up to the next shelf and take advantage of the mainstream enterprise adoption that’s available to us now.
Jim Mazzola: Okay. I want to make sure we get everyone’s question. So we should probably move to the next question, operator.
Operator: Yes. Our next question comes from Suraj Kalia with Oppenheimer. Your line is open.
Suraj Kalia: Leslie, can you hear me all right?
Leslie Trigg: Yes.
Suraj Kalia: Perfect. So Leslie, just one question, but a multi-part question. And I have to confess Leslie, I cannot connect the dots on the reasons for the shortfall, especially given the Polish commentary over the last three years, the guidance cuts almost every year. What I’m trying to understand is, I understand Q1 to Q2 may be something short term. But is it more of an issue of internal forecasting versus execution capabilities I guess that’s one of the things that I’m trying to understand. Has price sensitivity increased because you all did implement an 8% consolidated price increase, is that a factor? Was there any geographic pockets of weakness? And finally, I would ask is you mentioned multiple times about 50, 100s of console deals in the pipeline. Are these deals actually signed? Is there a PO in hand I know that a multipart question, but hopefully, you can help me reconcile — I’m having a very hard time connecting the dots here? Thank you.
Leslie Trigg: Sure. Well, yes, let me kind of take that one piece at a time. So you asked about sort of the connecting the dots on the magnitude of the impact here for the second half of the year. There were a couple of factors we considered in developing our guidance for the back half of the year. First, we do expect some level of disruption from this sales force restructuring, the process restructuring. And so that certainly was an element of our thought process in guidance development as we implement and continue to implement all the changes. Second, I mentioned that the complexion of our pipeline has changed in a good way. It is populated much more heavily with these larger enterprise agreements that can be 50-plus consoles. And so at that level, it really doesn’t take all that many deals to arrive at a revenue impact that’s pretty significant. $40 million is roughly a dozen or so deals. And so hopefully, that provides a little bit of color and a connection point for you there on the first part of your question. Second, you asked about price sensitivity. No. We really have not experienced price sensitivity as a factor because in the acute and subacute setting. And again, this has been well demonstrated and documented and published on the magnitude of the cost savings that Tablo drives in the acute and subacute setting is extremely significant, 50% to 70% down on the total cost of a hospital’s expense line for dialysis after the implementation of in-sourcing with Tablo. So no price sensitivity has not — really has not been a factor at all. You then asked about the pipeline. You have issues in forecasting and are these deals with a PO in hand. I mean the definition of a pipeline is future forward. These are deals that are at various stages in our sales cycle. We stage them just like any capital equipment company. And so when I talk about the strength of the pipeline, the size of the pipeline and the stage of the pipeline, we’re referring to our visibility and our future opportunities that are in front of us across the end market. Of course, going lastly to forecasting, one of the reasons why we see the need to adjust and mature our sales process and methodologies and teams are because we do believe it will reap benefits in the way that we execute against forecasting. We think it will give us greater visibility, greater control and greater predictability moving forward.
Jim Mazzola: Great. Thanks Suraj. Next question, operator.
Operator: Our next question will come from Kristen Stewart with CL King. Your line is open.
Kristen Stewart: Hi. Thanks for taking my question. I just wanted to focus on the expenses of the company. I think you had mentioned that operating expenses were going to be about $120 million this year. And if I heard you right, you said $100 million for run rate for 2025. What kind of gives you the confidence that you can make these cuts? Where are they coming from and just the confidence that this is going to be more disruptive from a selling organization perspective?
Nabeel Ahmed: Yes. Kristen, with respect to the — so first of all, you are right, we guided to about $120 million in OpEx for ’24 and a run rate of about $100 million in 2025. And that cuts this time are all around the areas that Leslie talked about. And it’s really for us about rightsizing our OpEx structure with both our revenue levels, number one. And then number two, with our commitment to making sure that we remain on the path to profitability.
Jim Mazzola: Great. Thanks, Kristen. Operator, we can move to the next question.
Operator: Our next question comes from Stephanie Piazzola with Bank of America Securities. Your line is open.
Stephanie Piazzola: Hi. Thanks for taking the question. I just wanted to follow up about the guidance for this year, moving over by $40 million and maybe a little bit more about how you thought about this being the new guidance level, you said it would be similar second half to first half. But maybe if you could dive a little bit more into the underlying assumptions here and confidence in this being the right spot, just with some expected disruption from the commercial execution changes. Thank you.
Nabeel Ahmed: Yes, Stephanie. So first of all, when we think about guidance for any period, we start with kind of the recurring revenue base, which for us is consumables and then the service and other line in our P&L. That for the first half is about $40 million, just under $40 million, and we would expect that to grow a little bit here in the second half or at least stay stable, all else being equal. So you start out for the second half with $40 million of kind of recurring revenue base the implied 2H total revenue is $55 million, which leaves consoles at about $50 million. And again, if you look at what we’ve done in the first half, console revenue was about $60 million. So again, it’s that same level of console placement in the second half as we expect — as we did in the first half of the year. That’s how we thought about the guidance.
Jim Mazzola: Okay. Thanks, Stephanie. I just want to make sure we get everybody in here. So operator, can we move to the next question please?
Operator: Your next question is from Josh Jennings with TD Cowen. Your line is open. Josh, your line is now open. Okay. Our next question will come from Drew Ranieri with Morgan Stanley. Your line is now open.
Drew Ranieri: Hi Leslie, hi Nabeel, thanks for taking the questions. Maybe just one, and it’s on 2025. But when I think about your installed base where you’re kind of ending the second quarter at least kind of like what our numbers you’re pointing to, and it kind of gets us to recurring revenue on an annualized basis of about $110 million. So is that at least a good point to start for 2025 and then we can think about levering on maybe a similar revenue number for quarterly consoles, somewhere around that like $7 million per quarter. It sounds like you have at least some visibility in the back half numbers, but just thinking about holding that constant for next year?
Nabeel Ahmed: Yeah. Hey, Drew. So, a couple of things. So, first of all, we’re not guiding to 2025 or for any period beyond 2024 right now here, but let me tell you maybe the way we think about the components, right? So if you unpack recurring revenues on the consumable side, we assume between four and five treatments per console per week in the acute setting, and again, we have this notion of some consoles need to ramp up, some obviously do more, some do a bit less, but on average it’s between four and five treatments per console per week in the acute, and then at home it’s between three and four treatments per console per week in the home setting. So that’s kind of how you get the consumable number. Service, it’s the service contract and then they renew, they typically renew in the 90% zone. So again, that’s kind of the assumption that we have used at least as we think about the second half of the year, and then you’re left with the console number. So I don’t want to comment on a specific number, but hopefully that helps you with the construct of how to think about 2025.
Drew Ranieri: You also gave 24 run rate for…
Nabeel Ahmed: And yeah, and ’24 — thank you, and then ’24 run rate, yeah, it’s $80 million from a run rate perspective for recurring revs given our guidance. Okay. Thanks.
Operator: Okay. Our next question comes from Josh Jennings with TD Cowen. Your line is open.
Josh Jennings: Hi, thanks for taking the question. Can you hear me okay?
Leslie Trigg: Yeah.
Josh Jennings: Okay, great. Sorry for the technical issue. I wanted to just ask about the pipeline. I mean, it sounds like it’s flush. Are you seeing some of these pipeline orders, when they don’t convert, fall out of the pipeline? Any help thinking through that dynamic? And if not, should we just be thinking about the delays in pipeline conversion being pushed out to 2025? And so, we could see a bolus of system revenues and increase in install base in 2025?
Leslie Trigg: Yeah, I’ll take that. Thanks, Josh. Short answer, no, we are not seeing deals fall out of this pipeline. We are seeing deals push out from the quarter in which we expect them to close into another quarter. And so, I think what we want to try to do better at and get stronger on is converting the pipeline to close and revenue on the timeline that we anticipate. So, that’s kind of point one. But no, the pipeline has continued to grow. And we have not seen really any movement of these deals falling out of the pipeline. Yeah. So the second part of your question, as we think about 2025, yes, our expectation is that the deals that are in the pipeline, those that don’t close in 2024, will still be available to us in 2025. And that’s really been, that’s not new for us. That is not a new phenomenon. We really have not had deals falling out of our pipeline really at any point in time. I think, again, we were overly focused in hindsight on TabloCart and late to the party to realize that there was another reason, another factor behind the elongation of this sales cycle and behind why some of these deals were not closing or coming to fruition when we intended them to. And those are exactly the sales execution challenges that we’re attacking and expect to make significant progress on here in the next couple of quarters.
Operator: I show no further questions in the queue at this time. I would now like to turn the call back to Leslie Trigg for closing remarks.
Leslie Trigg: Great. Thanks to everybody for joining today. I’d like to close by thanking our entire team for the very meaningful difference that they’re making every day in the lives of dialysis patients and their families, as well as providers. We look forward to seeing many of you in investor conferences in September, and I hope you have a great evening. Thank you.
Operator: This does conclude today’s conference call. Thank you for your participation. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.